$KPTI
Karyopharm Therapeutics Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517158670 Filed on May 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $3.000K $68.00K $0.00
YoY Change -94.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.640M $6.260M $5.550M
YoY Change 11.41% 12.79% 2.78%
% of Gross Profit
Research & Development $23.12M $24.08M $21.80M
YoY Change -5.94% 10.5% 5.03%
% of Gross Profit
Depreciation & Amortization $180.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 28.57%
% of Gross Profit
Operating Expenses $29.76M $30.35M $27.35M
YoY Change -2.55% 10.96% 4.59%
Operating Profit -$29.75M -$30.28M -$27.35M
YoY Change -2.38% 10.71% 4.59%
Interest Expense $410.0K $400.0K $290.0K
YoY Change 24.24% 37.93% 107.14%
% of Operating Profit
Other Income/Expense, Net $383.0K $385.0K $290.0K
YoY Change 20.44% 32.76% 249.4%
Pretax Income -$29.37M -$29.89M -$27.06M
YoY Change -2.62% 10.48% 3.79%
Income Tax $18.00K $23.00K
% Of Pretax Income
Net Earnings -$29.39M -$29.92M -$27.06M
YoY Change -2.56% 10.56% 3.81%
Net Earnings / Revenue -979566.67% -43995.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$641.3K -$714.3K -$754.2K
COMMON SHARES
Basic Shares Outstanding 47.12M shares 41.90M shares 35.88M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.5M $109.9M $136.4M
YoY Change 16.95% -19.43% -44.64%
Cash & Equivalents $55.38M $25.58M $42.19M
Short-Term Investments $88.10M $84.30M $94.20M
Other Short-Term Assets $2.300M $2.300M $1.700M
YoY Change 53.33% 35.29% -41.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $145.7M $112.2M $138.1M
YoY Change 17.33% -18.76% -44.59%
LONG-TERM ASSETS
Property, Plant & Equipment $2.473M $2.654M $3.343M
YoY Change -21.99% -20.61% 1.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.30M $40.30M $50.20M
YoY Change -13.05% -19.72% 30.39%
Other Assets $300.0K $15.00K $500.0K
YoY Change 170.27% -97.0% 0.0%
Total Long-Term Assets $40.03M $43.21M $53.99M
YoY Change -14.29% -19.98% 26.39%
TOTAL ASSETS
Total Short-Term Assets $145.7M $112.2M $138.1M
Total Long-Term Assets $40.03M $43.21M $53.99M
Total Assets $185.8M $155.4M $192.1M
YoY Change 8.69% -19.1% -34.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.247M $4.245M $4.109M
YoY Change -20.08% 3.31% -40.94%
Accrued Expenses $12.88M $10.74M $8.652M
YoY Change 15.87% 24.13% 16.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.52M $15.48M $13.22M
YoY Change 12.86% 17.09% -10.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.500M $1.600M $1.900M
YoY Change -16.67% -15.79% 5.56%
Total Long-Term Liabilities $1.500M $1.600M $1.900M
YoY Change -16.67% -15.79% 5.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.52M $15.48M $13.22M
Total Long-Term Liabilities $1.500M $1.600M $1.900M
Total Liabilities $19.04M $17.07M $15.10M
YoY Change 9.84% 13.07% -8.57%
SHAREHOLDERS EQUITY
Retained Earnings -$425.7M -$396.3M -$283.6M
YoY Change 35.67% 39.74% 72.48%
Common Stock $592.5M $534.8M $460.5M
YoY Change 26.84% 16.14% 4.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $166.7M $138.4M $177.0M
YoY Change
Total Liabilities & Shareholders Equity $185.8M $155.4M $192.1M
YoY Change 8.69% -19.1% -34.21%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$29.39M -$29.92M -$27.06M
YoY Change -2.56% 10.56% 3.81%
Depreciation, Depletion And Amortization $180.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 28.57%
Cash From Operating Activities -$21.72M -$24.71M -$23.17M
YoY Change 3.97% 6.65% 14.53%
INVESTING ACTIVITIES
Capital Expenditures $39.00K
YoY Change -78.09%
Acquisitions
YoY Change
Other Investing Activities -$1.140M $550.0K $6.790M
YoY Change -107.03% -91.9% -104.0%
Cash From Investing Activities -$1.140M $550.0K $6.750M
YoY Change -107.03% -91.85% -103.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 52.57M 60.00K 200.0K
YoY Change 21804.17% -70.0% -99.78%
NET CHANGE
Cash From Operating Activities -21.72M -24.71M -23.17M
Cash From Investing Activities -1.140M 550.0K 6.750M
Cash From Financing Activities 52.57M 60.00K 200.0K
Net Change In Cash 29.71M -24.09M -16.22M
YoY Change -770.65% 48.5% -83.64%
FREE CASH FLOW
Cash From Operating Activities -$21.72M -$24.71M -$23.17M
Capital Expenditures $39.00K
Free Cash Flow -$23.21M
YoY Change 13.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
402000
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47118234 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42188000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1637000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
148721000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
125000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2028000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41902255 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41902255 shares
CY2017Q1 us-gaap Assets
Assets
155435000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1591000
CY2017Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
286000
CY2017Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
46 Securities
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4245000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-204000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
124564000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10740000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2654000
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4682000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534838000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
124660000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
75993000
CY2017Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25577000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q1 us-gaap Short Term Investments
ShortTermInvestments
84307000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
138363000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396275000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2146000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
279000
CY2017Q1 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2017Q1 kpti Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
27701 sqft
CY2017Q1 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8359000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58358000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3476000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-267000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
112230000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163239000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41887829 shares
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
210000
CY2017Q1 us-gaap Liabilities
Liabilities
17072000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155435000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15481000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
270000
CY2017Q1 us-gaap Long Term Investments
LongTermInvestments
40257000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41887829 shares
CY2016Q4 us-gaap Assets
Assets
180385000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1666000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
131636000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528617000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125478000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
95949000
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49663000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
58 Securities
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4751000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125323000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11362000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
83000
CY2016Q4 us-gaap Liabilities
Liabilities
18142000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180385000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16476000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
45434000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2836000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4681000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
79889000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
162243000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366104000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2084000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
479000
CY2016Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6855000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2015Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-24086000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6264000
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
16000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
183000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29847000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
68000
CY2017Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
69000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
301000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25075000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-498000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
30347000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-29917000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29894000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
549000
CY2017Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25624000
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-522000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
61000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30279000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
400000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24708000
CY2017Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24083000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
57000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5909000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41894796 shares
CY2017Q1 kpti Rights Received For Each Restricted Share Unit
RightsReceivedForEachRestrictedShareUnit
1 Right
CY2017Q1 kpti Deferred Financing Costs Included In Accounts Payable
DeferredFinancingCostsIncludedInAccountsPayable
15000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-314000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16170000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5554000
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
48000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
179000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26683000
CY2016Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
12000
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
288000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
290000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
59003000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2282000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
27349000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-27059000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27059000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6751000
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
65793000
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
294000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-243000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27349000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
196000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
343000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
286000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23165000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21795000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
196000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5158000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35878502 shares

Files In Submission

Name View Source Status
0001193125-17-158670-index-headers.html Edgar Link pending
0001193125-17-158670-index.html Edgar Link pending
0001193125-17-158670.txt Edgar Link pending
0001193125-17-158670-xbrl.zip Edgar Link pending
d156134d10q.htm Edgar Link pending
d156134dex311.htm Edgar Link pending
d156134dex312.htm Edgar Link pending
d156134dex321.htm Edgar Link pending
d156134dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20170331.xml Edgar Link completed
kpti-20170331.xsd Edgar Link pending
kpti-20170331_cal.xml Edgar Link unprocessable
kpti-20170331_def.xml Edgar Link unprocessable
kpti-20170331_lab.xml Edgar Link unprocessable
kpti-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending